NASDAQ:CNSY Plus Therapeutics (CNSY) Stock Price, News & Analysis $1.87 -0.08 (-4.10%) Closing price 09/24/2026 04:00 PM EasternExtended Trading$1.89 +0.02 (+1.07%) As of 09/24/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFinancialsNews and TrendsSEC Filings About Plus Therapeutics Stock (NASDAQ:CNSY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Plus Therapeutics alerts:Sign Up Key Stats Today's Range$1.86▼$1.9650-Day Range N/A52-Week Range$1.86▼$23.43Volume86,037 shsAverage Volume75,820 shsMarket Capitalization$14.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingReduce Company Overview Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. The company’s lead investigational product is Rhenium-186 NanoLiposome, or 186RNL, a nanoliposome-based formulation designed to deliver the beta-emitting radioisotope rhenium-186 directly to tumor sites. Plus Therapeutics is evaluating 186RNL in clinical programs for recurrent glioblastoma and leptomeningeal metastases, cancers that spread to the membranes surrounding the brain and spinal cord. The company’s approach is intended to provide localized radiation while limiting exposure to surrounding healthy tissue. These programs remain investigational and have not established the product as an approved commercial treatment. Based in Austin, Texas, Plus Therapeutics serves the oncology market through research and clinical development activities conducted primarily in the United States. Marc Hedrick, M.D., has served as the company’s president and chief executive officer. The company has also pursued collaborations and government-supported development efforts related to its targeted radiotherapeutic platform.AI Generated. May Contain Errors. Read More Plus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks9th Percentile Overall ScoreCNSY MarketRank™: Plus Therapeutics scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingReduce Consensus RatingPlus Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoveragePlus Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Plus Therapeutics' stock forecast and price target. Earnings and Valuation0.7 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Plus Therapeutics are expected to grow in the coming year, from ($4.08) to ($2.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Plus Therapeutics is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPlus Therapeutics has a P/B Ratio of 2.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.81% of the float of Plus Therapeutics has been sold short.Short Interest Ratio / Days to CoverPlus Therapeutics has a short interest ratio ("days to cover") of 8.68.Change versus previous monthShort interest in Plus Therapeutics has recently increased by 0.42%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPlus Therapeutics does not currently pay a dividend.Dividend GrowthPlus Therapeutics does not have a long track record of dividend growth. News and Social Media1.5 / 5News Sentiment-0.60 News SentimentPlus Therapeutics has a news sentiment score of -0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Plus Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for CNSY on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows2 people have added Plus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Plus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.50% of the stock of Plus Therapeutics is held by insiders.Percentage Held by Institutions3.28% of the stock of Plus Therapeutics is held by institutions.Read more about Plus Therapeutics' insider trading history. Receive CNSY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Plus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNSY Stock News HeadlinesCerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered LivesSeptember 22 at 7:30 AM | globenewswire.comCNSY Q3 EPS Forecast Decreased by Ascendiant Capital MarketsSeptember 19, 2026 | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain. | InvestorPlace (Ad)Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics DivisionSeptember 16, 2026 | globenewswire.comCERENOME INCSeptember 11, 2026 | finanznachrichten.deCerenome, Inc. Enters Into Up To $20 Million Senior Secured Financing Facility With 3i, LP With Royalty-Based RepaymentSeptember 10, 2026 | marketscreener.comMCerenome Announces Up to $20 Million Financing Facility with Royalty-Based RepaymentSeptember 10, 2026 | globenewswire.comCerenome Launches New Corporate Identity as Integrated CNS Oncology CompanyAugust 27, 2026 | markets.businessinsider.comSee More Headlines CNSY Stock Analysis - Frequently Asked Questions How have CNSY shares performed this year? Plus Therapeutics' stock was trading at $3.91 on August 5, 2026. Since then, CNSY stock has decreased by 52.2% and is now trading at $1.87. How were Plus Therapeutics' earnings last quarter? Plus Therapeutics, Inc. (NASDAQ:CNSY) released its quarterly earnings results on Friday, August, 14th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.96) by $0.35. The company had revenue of $0.41 million for the quarter. Plus Therapeutics had a negative net margin of 620.70% and a negative trailing twelve-month return on equity of 394.17%. How do I buy shares of Plus Therapeutics? Shares of CNSY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/14/2026Today9/24/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 2 weeks, CNSY's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:CNSY CIK1095981 Webwww.cerenome.com Phone(737) 255-7194Fax858-450-4335Employees28Year Founded1996Profitability EPS (Trailing Twelve Months)($3.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$22.39 million Net Margins-620.70% Pretax Margin-620.70% Return on Equity-394.17% Return on Assets-151.36% Debt Debt-to-Equity RatioN/A Current Ratio1.37 Quick Ratio0.65 Sales & Book Value Annual Sales$5.21 million Price / Sales2.72 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book2.60Miscellaneous Outstanding Shares7,590,000Free Float7,400,000Market Cap$14.19 million OptionableN/A Beta1.39 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:CNSY) was last updated on 9/25/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
